Switch theme
Sign up to access all valuation multiples
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Commercial sales segment, Contract Development & Manufacturing Organization segment, and Other segment. The majority of revenue is derived from the Commercial sales segment. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
2007
153
LTM Revenue $732M
LTM EBITDA $214M
$3.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bora Pharmaceuticals has a last 12-month revenue (LTM) of $732M and a last 12-month EBITDA of $214M.
In the most recent fiscal year, Bora Pharmaceuticals achieved revenue of $665M and an EBITDA of $223M.
Bora Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bora Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $732M | XXX | $665M | XXX | XXX | XXX |
| Gross Profit | $314M | XXX | $267M | XXX | XXX | XXX |
| Gross Margin | 43% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $214M | XXX | $223M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $153M | XXX | $117M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $158M | XXX | $136M | XXX | XXX | XXX |
| Net Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $425M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Bora Pharmaceuticals's stock price is TWD 814 (or $28).
Bora Pharmaceuticals has current market cap of TWD 84.2B (or $2.9B), and EV of TWD 97.0B (or $3.4B).
See Bora Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.4B | $2.9B | XXX | XXX | XXX | XXX | $1.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Bora Pharmaceuticals has market cap of $2.9B and EV of $3.4B.
Bora Pharmaceuticals's trades at 5.0x EV/Revenue multiple, and 15.0x EV/EBITDA.
Equity research analysts estimate Bora Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bora Pharmaceuticals has a P/E ratio of 18.4x.
See valuation multiples for Bora Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 15.7x | XXX | 15.0x | XXX | XXX | XXX |
| EV/EBIT | 21.9x | XXX | 28.7x | XXX | XXX | XXX |
| EV/Gross Profit | 10.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.4x | XXX | 21.4x | XXX | XXX | XXX |
| EV/FCF | 21.5x | XXX | 330.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBora Pharmaceuticals's last 12 month revenue growth is 23%
Bora Pharmaceuticals's revenue per employee in the last FY averaged $4.3M, while opex per employee averaged $1.0M for the same period.
Bora Pharmaceuticals's rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bora Pharmaceuticals's rule of X is 88% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bora Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 58% | XXX | 57% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 88% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $4.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bora Pharmaceuticals acquired XXX companies to date.
Last acquisition by Bora Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Bora Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bora Pharmaceuticals founded? | Bora Pharmaceuticals was founded in 2007. |
| Where is Bora Pharmaceuticals headquartered? | Bora Pharmaceuticals is headquartered in Taiwan. |
| How many employees does Bora Pharmaceuticals have? | As of today, Bora Pharmaceuticals has 153 employees. |
| Is Bora Pharmaceuticals publicy listed? | Yes, Bora Pharmaceuticals is a public company listed on TAI. |
| What is the stock symbol of Bora Pharmaceuticals? | Bora Pharmaceuticals trades under 6472 ticker. |
| When did Bora Pharmaceuticals go public? | Bora Pharmaceuticals went public in 2014. |
| Who are competitors of Bora Pharmaceuticals? | Similar companies to Bora Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bora Pharmaceuticals? | Bora Pharmaceuticals's current market cap is $2.9B |
| What is the current revenue of Bora Pharmaceuticals? | Bora Pharmaceuticals's last 12 months revenue is $732M. |
| What is the current revenue growth of Bora Pharmaceuticals? | Bora Pharmaceuticals revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Bora Pharmaceuticals? | Current revenue multiple of Bora Pharmaceuticals is 4.6x. |
| Is Bora Pharmaceuticals profitable? | Yes, Bora Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bora Pharmaceuticals? | Bora Pharmaceuticals's last 12 months EBITDA is $214M. |
| What is Bora Pharmaceuticals's EBITDA margin? | Bora Pharmaceuticals's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Bora Pharmaceuticals? | Current EBITDA multiple of Bora Pharmaceuticals is 15.7x. |
| What is the current FCF of Bora Pharmaceuticals? | Bora Pharmaceuticals's last 12 months FCF is $156M. |
| What is Bora Pharmaceuticals's FCF margin? | Bora Pharmaceuticals's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Bora Pharmaceuticals? | Current FCF multiple of Bora Pharmaceuticals is 21.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
